Deep Analysis of Impact of COVID-19 on “Brain Tumor Diagnosis And Therapeutics Market 2019-2025” Growth Worldwide….
The global brain tumor
diagnosis and therapeutics market
size is expected to reach USD 773.1
million by 2025, according to a new report by Grand View Research, Inc. The
market is expected to pose lucrative growth over the forecast period, owing to
increasing incidence of various brain cancers, particularly glioblastoma,
coupled with rising geriatric population.
With Covid-19 infections rising globally, the
apprehension regarding a shortage of essential life-saving devices and other
essential medical supplies in order to prevent the spread of this pandemic and
provide optimum care to the infected also widens. In addition, till a
pharmacological treatment is developed, ventilators act as a vital treatment
preference for the COVID-19 patients, who may require critical care. Moreover,
there is an urgent need for a rapid acceleration in the manufacturing process
for a wide range of test-kits (antibody tests, self-administered, and others).
The report will account for Covid19 as a key market contributor.
Increasing Public-Private Partnerships
(PPPs) in the health sector, which are modernizing diagnostic imaging and
radiology services, are supporting the expansion of this industry. Emerging
technologies like Sodium Magnetic Resonance Imaging(23Na MRI), Positron
Emission Tomography (PET), and Chemical Exchange Saturation Transfer (CEST) are
used to detect the response of brain tumors in multicenter clinical trial
settings. In addition, these technologies are helpful in quantitatively imaging
tumor response to therapies, thereby promoting their use during treatment.
These technologies have the potential
to extend MRI beyond anatomical imaging by providing information on physiology
and cellular metabolism, thereby increasing the efficiency of diagnosis. Hence,
the market is expected to witness productive growth over the forecast period.
Moreover, ongoing research in
molecular diagnostics to understand cell biology at cellular level of
malignancy and identification of gene mutations associated with malignancy is
anticipated to significantly contribute toward the growth of the industry.
To Request Sample Copy of this report, click the link:
On the other hand, high cost of
diagnosing brain tumors, which ranges from USD 450 to 12,200, is likely to
hinder the growth of the global brain tumor diagnosis market.
Further Key Findings From the Study
Suggest:
·
CT scan segment held a
lucrative revenue share in 2015 and is also likely to grow at a significant
rate during the forecast period
·
Chemotherapy is anticipated to
witness the fastest growth over the forecast period owing to presence of a
large research pipeline by the industry players.
·
North America is expected to
dominate the brain tumor diagnosis and therapeutics market, owing to developed
healthcare infrastructure coupled with rising awareness regarding advanced
technologies amongst the population in this region. In addition, increasing
consumer disposable income supported by healthcare insurance and reimbursement
policies in the U.S. is expected to spur growth.
·
Some of the key players for the
market are GE Healthcare; Hitachi, Ltd.; Philips Healthcare; Siemens
Healthineers; Toshiba Corporation; Fujifilm Corporation; Shimadzu Corporation;
Carestream Health; Merck & Co.; Astra Zeneca; Bristol Myer Squibb;
Novartis; and Roche Diagnostics.
The global brain tumor diagnosis and therapeutics market size
was valued at USD 354.9 million in 2015 and is expected to grow at a CAGR of
8.1% over the forecast period. Rising prevalence of such cancer and growing
geriatric population are key drivers expected to nurture growth of brain tumor
diagnosis market worldwide.
As per statistics published by the WHO in 2012, more than14
million new cases of cancer and about 8.2 million deaths were reported; thus
alerting the healthcare fraternity to the augmenting growth of the disease.
Furthermore, it stated that morbidity is expected to increase by about 70.0%
over the next two decades. Similar data was published by the Global Health
Observatory (GHO) in 2015, which stated that the number of premature deaths due
to cancer is expected to increase by 44.0% by 2030.
As per the Central Brain Tumor Registry of the United States
(CBTRUS) statistical report 2016, an estimated 79,270 new cases of primary
malignant, nonmalignant, and other CNS cancers are anticipated to be diagnosed
in the U.S. in 2017 (26,070 primary malignant and 53,200 nonmalignant).
Increasing prevalence of brain cancer cases across the globe is expected to
propel the demand of brain tumor diagnosis over the forecast period.
Population above 60 years of age forms the target demographic
segment for this vertical, as this population subset is more prone to
neurological conditions. Advancement of diagnostics equipment increases the
lifespan of this demographic and improves the quality of life for those suffering
from neurological conditions. Hence, presence of a large geriatric population
pool is considered as a vital driver for this industry.
Have any Query? Ask our Experts:
Grand View Research has segmented the global brain tumor
diagnosis and therapeutics market on the basis of type, therapeutics:
Brain Tumor Diagnosis Type Outlook
(Revenue, USD Million, 2014 - 2025)
·
MRI
·
CT Scan
·
Tissue Sampling
·
PET-CT Scan
·
Cerebral Arteriogram
·
Lumbar Puncture
·
Molecular Testing
·
EEG
Brain Tumor Therapeutics Outlook (Revenue,
USD Million, 2014 - 2025)
·
Surgery
·
Radiation Therapy
·
Chemotherapy
·
Immunotherapy
·
Targeted Therapy
About Grand View Research
Grand View Research, Inc. is a U.S.
based market research and consulting company, registered in the State of
California and headquartered in San Francisco. The company provides syndicated
research reports, customized research reports, and consulting services. To help
clients make informed business decisions, we offer market intelligence studies
ensuring relevant and fact-based research across a range of industries, from
technology to chemicals, materials and healthcare.
Comments
Post a Comment